Baiteng Zhao Acquires Shares in Whitehawk Therapeutics
Baiteng Zhao purchased 38,040 shares of Whitehawk Therapeutics on June 12, 2026.
Key Points
- Baiteng Zhao bought 38,040 shares of Whitehawk Therapeutics, Inc. (WHWK) on June 12, 2026.
- Whitehawk Therapeutics has a market cap of approximately $202.8 million and trades on NasdaqCM.
- Analysts have set a mean price target of $6.50 for WHWK, with a 'buy' consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 12, 2026, Baiteng Zhao made a notable move by purchasing 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK). This insider buying activity adds to the interest in the biotechnology company, which is working on innovative cancer treatments.
Other Institutional Activity in Whitehawk Therapeutics
Several institutional investors have maintained their positions in Whitehawk Therapeutics. QVT Financial LP holds 4,615,709 shares valued at approximately $15.9 million. Similarly, Orbimed Advisors LLC holds 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC has a stake of 3,700,000 shares, valued at roughly $12.8 million. Acuta Capital Partners, LLC owns 3,410,402 shares valued at $11.8 million, while Avoro Capital Advisors LLC holds 2,849,402 shares worth about $9.8 million.
Whitehawk Therapeutics, Inc. Stock Down 11.3%
Shares of Whitehawk Therapeutics (NasdaqCM: WHWK) traded around $4.16 recently. The company has a market cap of approximately $202.8 million. Its stock has seen a 52-week low of $1.57 and a high of $5.50. Whitehawk Therapeutics boasts a current ratio of 11.356, reflecting strong liquidity.
$WHWK stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Whitehawk Therapeutics, Inc. is not yet profitable, with an EPS of -$2.49. The company's return on equity is -68.54%, and it has a net margin of 0.0%. Investors are looking ahead to the next earnings report due on August 6, 2026.
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, several insiders, including Castelein Caley, Desai Neil, Reeve Emma, Maroun Richard, Zhao Baiteng, and Aghazadeh Behzad, each acquired 38,040 shares of Whitehawk Therapeutics. These purchases were not part of a pre-planned trading program.
Analysts Set New Price Targets
On April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics with a 'buy' rating and an $8.00 price target. Previously, on December 22, 2025, Jones Trading also started coverage with a 'buy' rating and a $7.00 target. The consensus among analysts is a 'buy' rating with an average target price of $6.50.
About Whitehawk Therapeutics
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company based in Morristown, New Jersey. It focuses on developing next-generation antibody-drug conjugates (ADCs) to treat cancer. Led by CEO Dr. David J. Lennon, the company aims to advance oncology therapeutics by leveraging its expertise in tumor biology.
Bottom Line
The recent insider buying activity by Baiteng Zhao and others at Whitehawk Therapeutics highlights ongoing interest in the company's future prospects. With a market cap of around $202.8 million and a 'buy' consensus among analysts, investors continue to monitor this clinical-stage biotech firm. Keep in mind that insider transactions are disclosed after the fact and may not indicate current trading intentions.
Get Whitehawk Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $WHWK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.